Cargando…
Accumulation of ALDH1-positive cells after neoadjuvant chemotherapy predicts treatment resistance and prognosticates poor outcome in ovarian cancer
Although ovarian cancer is a highly chemosensitive disease, it is only infrequently cured. One of the major reasons lies in the presence of drug-resistant cancer stem-like cells, sufficient to fuel recurrence. We phenotyped cancer stem-like cells by flow cytometry and immunohistochemistry in 55 matc...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4599280/ https://www.ncbi.nlm.nih.gov/pubmed/25999351 |
_version_ | 1782394222633025536 |
---|---|
author | Ayub, Tiyasha H. Keyver-Paik, Mignon-Denise Debald, Manuel Rostamzadeh, Babak Thiesler, Thore Schröder, Lars Barchet, Winfried Abramian, Alina Kaiser, Christina Kristiansen, Glen Kuhn, Walther Kübler, Kirsten |
author_facet | Ayub, Tiyasha H. Keyver-Paik, Mignon-Denise Debald, Manuel Rostamzadeh, Babak Thiesler, Thore Schröder, Lars Barchet, Winfried Abramian, Alina Kaiser, Christina Kristiansen, Glen Kuhn, Walther Kübler, Kirsten |
author_sort | Ayub, Tiyasha H. |
collection | PubMed |
description | Although ovarian cancer is a highly chemosensitive disease, it is only infrequently cured. One of the major reasons lies in the presence of drug-resistant cancer stem-like cells, sufficient to fuel recurrence. We phenotyped cancer stem-like cells by flow cytometry and immunohistochemistry in 55 matched samples before and after taxane/platinum-based neoadjuvant chemotherapy. All used markers of stemness (ALDH1, CD24, CD117, CD133) isolated low frequencies of malignant cells. ALDH1 was the most valuable marker for tracking stemness in vivo. The enrichment of ALDH1 expression after treatment was associated with a poor response to chemotherapy, with platinum resistance and independently prognosticated unfavorable outcome. Our results suggest that increased ALDH1 expression after treatment identifies patients with aggressive tumor phenotypes. |
format | Online Article Text |
id | pubmed-4599280 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-45992802015-10-26 Accumulation of ALDH1-positive cells after neoadjuvant chemotherapy predicts treatment resistance and prognosticates poor outcome in ovarian cancer Ayub, Tiyasha H. Keyver-Paik, Mignon-Denise Debald, Manuel Rostamzadeh, Babak Thiesler, Thore Schröder, Lars Barchet, Winfried Abramian, Alina Kaiser, Christina Kristiansen, Glen Kuhn, Walther Kübler, Kirsten Oncotarget Research Paper Although ovarian cancer is a highly chemosensitive disease, it is only infrequently cured. One of the major reasons lies in the presence of drug-resistant cancer stem-like cells, sufficient to fuel recurrence. We phenotyped cancer stem-like cells by flow cytometry and immunohistochemistry in 55 matched samples before and after taxane/platinum-based neoadjuvant chemotherapy. All used markers of stemness (ALDH1, CD24, CD117, CD133) isolated low frequencies of malignant cells. ALDH1 was the most valuable marker for tracking stemness in vivo. The enrichment of ALDH1 expression after treatment was associated with a poor response to chemotherapy, with platinum resistance and independently prognosticated unfavorable outcome. Our results suggest that increased ALDH1 expression after treatment identifies patients with aggressive tumor phenotypes. Impact Journals LLC 2015-05-11 /pmc/articles/PMC4599280/ /pubmed/25999351 Text en Copyright: © 2015 Ayub et al. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Paper Ayub, Tiyasha H. Keyver-Paik, Mignon-Denise Debald, Manuel Rostamzadeh, Babak Thiesler, Thore Schröder, Lars Barchet, Winfried Abramian, Alina Kaiser, Christina Kristiansen, Glen Kuhn, Walther Kübler, Kirsten Accumulation of ALDH1-positive cells after neoadjuvant chemotherapy predicts treatment resistance and prognosticates poor outcome in ovarian cancer |
title | Accumulation of ALDH1-positive cells after neoadjuvant chemotherapy predicts treatment resistance and prognosticates poor outcome in ovarian cancer |
title_full | Accumulation of ALDH1-positive cells after neoadjuvant chemotherapy predicts treatment resistance and prognosticates poor outcome in ovarian cancer |
title_fullStr | Accumulation of ALDH1-positive cells after neoadjuvant chemotherapy predicts treatment resistance and prognosticates poor outcome in ovarian cancer |
title_full_unstemmed | Accumulation of ALDH1-positive cells after neoadjuvant chemotherapy predicts treatment resistance and prognosticates poor outcome in ovarian cancer |
title_short | Accumulation of ALDH1-positive cells after neoadjuvant chemotherapy predicts treatment resistance and prognosticates poor outcome in ovarian cancer |
title_sort | accumulation of aldh1-positive cells after neoadjuvant chemotherapy predicts treatment resistance and prognosticates poor outcome in ovarian cancer |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4599280/ https://www.ncbi.nlm.nih.gov/pubmed/25999351 |
work_keys_str_mv | AT ayubtiyashah accumulationofaldh1positivecellsafterneoadjuvantchemotherapypredictstreatmentresistanceandprognosticatespooroutcomeinovariancancer AT keyverpaikmignondenise accumulationofaldh1positivecellsafterneoadjuvantchemotherapypredictstreatmentresistanceandprognosticatespooroutcomeinovariancancer AT debaldmanuel accumulationofaldh1positivecellsafterneoadjuvantchemotherapypredictstreatmentresistanceandprognosticatespooroutcomeinovariancancer AT rostamzadehbabak accumulationofaldh1positivecellsafterneoadjuvantchemotherapypredictstreatmentresistanceandprognosticatespooroutcomeinovariancancer AT thieslerthore accumulationofaldh1positivecellsafterneoadjuvantchemotherapypredictstreatmentresistanceandprognosticatespooroutcomeinovariancancer AT schroderlars accumulationofaldh1positivecellsafterneoadjuvantchemotherapypredictstreatmentresistanceandprognosticatespooroutcomeinovariancancer AT barchetwinfried accumulationofaldh1positivecellsafterneoadjuvantchemotherapypredictstreatmentresistanceandprognosticatespooroutcomeinovariancancer AT abramianalina accumulationofaldh1positivecellsafterneoadjuvantchemotherapypredictstreatmentresistanceandprognosticatespooroutcomeinovariancancer AT kaiserchristina accumulationofaldh1positivecellsafterneoadjuvantchemotherapypredictstreatmentresistanceandprognosticatespooroutcomeinovariancancer AT kristiansenglen accumulationofaldh1positivecellsafterneoadjuvantchemotherapypredictstreatmentresistanceandprognosticatespooroutcomeinovariancancer AT kuhnwalther accumulationofaldh1positivecellsafterneoadjuvantchemotherapypredictstreatmentresistanceandprognosticatespooroutcomeinovariancancer AT kublerkirsten accumulationofaldh1positivecellsafterneoadjuvantchemotherapypredictstreatmentresistanceandprognosticatespooroutcomeinovariancancer |